

Financial Tear Sheet

Corporate Profile

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, including glaucoma. In July 2017, the Company announced top-line results of its Phase 2 fixed-dose combination trial of trabodenoson and latanoprost for the treatment of glaucoma. The trial did not meet its primary efficacy endpoint and the Company has since discontinued development of trabodenoson in order to focus on evaluating strategic alternatives.

Primary IR Contact

US Corporate Headquarters:
Phone: 781-676-2100
E-mail: info@inotekpharma.com

Stock Performance

ITEK (Common Stock)

Exchange	NASDAQ (US Dollar)
Financial Status Indicator	C
Price	\$2.57
Change (%)	▲ 0.09 (3.63%)
Volume	102,142
52 Week High	\$7.40
52 Week Low	\$0.85
Market Cap	\$69,962,455
Rolling EPS	-1.39
PE Ratio	0
Shares Outstanding	27,222,745

Data as of 12/08/17 4:00 p.m. ET



Recent News & Events

Oct 12, 2017

[Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket Pharmaceuticals](#)

Sep 12, 2017

[INSERTING and REPLACING Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases](#)

Sep 12, 2017

[Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases](#)

SEC Filings

Filing Date	Form
12/04/17	DEFM14A
11/20/17	PRER14A
11/08/17	10-Q
10/26/17	SC 13D/A

There are currently no events scheduled.

Corporate Governance

David P. Southwell	President and Chief Executive Officer
Rudolf A. Baumgartner, MD	Executive Vice President, Chief Medical Officer
Dale Ritter	Vice President, Finance & Chief Accounting Officer
Claudine Prowse, PhD	Vice President, Strategy, Corporate Development & IRO

Data provided by Nasdaq. Minimum 15 minutes delayed.